EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Prospective, Blinded Study of Symptom Prevalence and Specificity of Porphyrin Precursors in Carriers of Acute Hepatic Porphyria

Mohsen Merati iD, Nanditha Jayakumar, Yuvraaj Kapoor, Hetanshi Naik, Manisha Balwani iD, Karl E Anderson, Herbert L Bonkovsky, Robert J Desnick, Brendan McGuire, John Phillips iD, D Montgomery Bissell, Bruce Wang iD

Liver International · 2025

DOI: 10.1111/liv.70156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Mohsen Merati und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Porphobilinogen, Porphyrias, Hepatic, Aminolevulinic Acid, Porphyrins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims This study aimed to characterise symptoms and assess the prevalence of elevated urine porphyrin precursors in first‐degree relatives of acute hepatic porphyria (AHP) patients who have never experienced acute attacks and had no previous AHP genetic or biochemical testing.

Methods

149 first‐degree relatives of confirmed AHP patients, previously unscreened for the family mutation, were recruited. All underwent genetic analysis, with 143 completing a study questionnaire and 118 undergoing urine analysis for delta aminolevulinic acid (ALA) and porphobilinogen (PBG). The questionnaire focused on symptoms, medical and family history, and quality of life.

Results

The study included 79 AHP mutation carriers and 70 non‐carriers. Carriers had significantly higher ALA (6.98 vs. 2.21 mg/g creatinine) and PBG levels (9.17 vs. 1.31 mg/g creatinine) than non‐carriers. Female carriers showed higher ALA (9.29 vs. 3.07 mg/g creatinine) and PBG levels (12.71 vs. 3.16 mg/g creatinine) than male carriers. Porphyria‐related symptoms were reported by 27% (21/77) of carriers compared to 15% (10/66) of non‐carriers, with carriers more likely to report dark urine and prolonged symptoms. Finally, 30.8% of carriers were asymptomatic high excreters (ASHE) with PBG levels exceeding four times the upper limit of normal (ULN).

Conclusions

Significant differences in porphyrin precursor excretion and symptom profiles were found between AHP mutation carriers and controls, as well as between female and male carriers. Female carriers are more likely to excrete porphyrin metabolites above the normal range. A larger than expected number of undiagnosed carriers are ASHE with levels greater than four times the ULN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PorphobilinogenPorphyrias, HepaticAminolevulinic AcidPorphyrinsHumansFemaleMaleAdultMiddle AgedProspective StudiesHeterozygotePrevalenceSurveys and QuestionnairesMutationAgedQuality of LifeYoung AdultPorphobilinogen Synthase

Stichwörter der Autor:innen

acute hepaticaminolevulinic acidgenetic carriersheme biosynthesismutationporphobilinogenporphyriaporphyrins

Substanzen

PorphobilinogenAminolevulinic AcidPorphyrinsPorphobilinogen Synthase

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • The Porphyrias Consortium, New York, New York, USA.
  • Stanford University, Stanford, California, USA.
  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Department of Preventive Medicine and Population Health, University of Texas Medical Branch Galveston, Galveston, Texas, USA.
  • Section of Gastroenterology and Hepatology, Wake Forrest University School of Medicine, Winston Salem, North Carolina, USA.

ORCID-Profile: Mohsen Merati, Manisha Balwani, John Phillips, Bruce Wang

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Merati, M., Jayakumar, N., Kapoor, Y., Naik, H., Balwani, M., Anderson, K. E., Bonkovsky, H. L., Desnick, R. J., McGuire, B., Phillips, J., Bissell, D. M., & Wang, B. (2025). A Prospective, Blinded Study of Symptom Prevalence and Specificity of Porphyrin Precursors in Carriers of Acute Hepatic Porphyria. Liver International. https://doi.org/10.1111/liv.70156

Vancouver

Merati M, Jayakumar N, Kapoor Y, Naik H, Balwani M, Anderson KE, et al. A Prospective, Blinded Study of Symptom Prevalence and Specificity of Porphyrin Precursors in Carriers of Acute Hepatic Porphyria. Liver International. 2025. doi:10.1111/liv.70156

BibTeX
@article{Merati2025,
  author = {Merati, Mohsen and Jayakumar, Nanditha and Kapoor, Yuvraaj and Naik, Hetanshi and Balwani, Manisha and Anderson, Karl E and Bonkovsky, Herbert L and Desnick, Robert J and McGuire, Brendan and Phillips, John and Bissell, D Montgomery and Wang, Bruce},
  title = {A Prospective, Blinded Study of Symptom Prevalence and Specificity of Porphyrin Precursors in Carriers of Acute Hepatic Porphyria},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70156}
}
Kostenlos starten →